Articles

Pfizer and Bristol-Myers Squibb fail to win FDA approval for Eliquis

Work will continue to advance the drug's approval in Europe and Japan, as well as to address FDA concerns
Written byJeffrey Bouley
| 2 min read

PRINCETON, N.J. & NEW YORK—Bristol-MyersSquibb Co. and Pfizer have announced that the U.S.Food and Drug Administration (FDA) recently issued a Complete ResponseLetter (CRL) regarding the New Drug Application (NDA) for Eliquis (apixaban)for the prevention of stroke and systemic embolism in patients with nonvalvularatrial fibrillation, failing to give them the approval they sought for the drug.

To continue reading this article, subscribe for FREE toDrug Discovery News Logo

Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

About the Author

Here are some related topics that may interest you:

Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Gloved hand holding a multiwell cell culture plate under a fluorescence microscope for spheroid analysis.
Using confocal live-cell imaging to characterize immune-mediated cytotoxicity over time.
Fluorescence microscopy image of cells displaying green and red fluorescent signals.
Using confocal live-cell imaging to assess treatment effects in spheroids, organoids, and co-cultures.
3D illustration of Y-shaped antibody molecules floating against a soft blue background, with a detailed antibody structure in the foreground.
From molecular developability to functional activity, integrated characterization strategies help inform lead selection and optimization in biologics discovery.